慢性乙型肝炎核苷(酸)类似物经治患者再治疗策略  

Re-treatment for relapsed patients after an initial nucleotide(s) analogue therapy in chronic hepatitis B

作　　者：陈士俊[1,2] 杜文军[1,2] 

机构地区：[1]山东大学附属传染病医院山东省肝病诊疗中心 [2]济南市传染病医院,济南250000

出　　处：《临床肝胆病杂志》2011年第12期1257-1258,1269,共3页Journal of Clinical Hepatology

摘　　要：核苷(酸)类似物在慢性乙型肝炎的临床治疗中的应用日益广泛,恰当处理核苷(酸)类似物经治患者的停药后复发及其再治疗、合理把握再治疗方案备受关注。核苷(酸)类似物经治患者可分为正在治疗和经治复发两大类。对于正在治疗的经治患者目前按照路线图的概念来进行管理;而对于经治复发的患者根据其初始治疗的不同应答情况可采用优化治疗及联合治疗的策略进行管理。Nucleotide（s） analogues have been widely used in the treatment of chronic hepatitis B. It is important to deal with the relapsed patients treated with an initial nucleotide （s） analogues therapy properly, and grasp of re - treatment program reasonably, Patients treated with nucleotide（s） analogues can be divided into two categories： being treated and relapsed after treatment. The first group of patients should be managed by the concept of the road map meanwhile the latter should be depending on the initial treatment response of combination therapy which can be used to optimize the treatment and management strategies.

关 键 词：肝炎 乙型 慢性 核酸类 核苷酸类和核苷类 抗病毒药 

分 类 号：R512.62[医药卫生—内科学]